Indication
Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.
Loading your page…
Loading your page…
Opioid-Related Disorders
Marketing Authorisation Holder: Camurus AB
EMA Authorisation: 20/11/2018
INN: buprenorphine
AI Drug & Interaction Analysis
Free account required
Ask Osler about Buvidal: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.